Cabotegravir, Rilpivirine (Cabenuva,Vocabria) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search for clinical
Cabotegravir sodium rilpivirine (Cabenuva, Vocabria) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search
Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection Published: 13 September 2024 Driving Better Decision-Making in Healthcare Page 1 Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection Technology Guidance from the MOH Drug Advisory Committee Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended cabotegravir with rilpivirine for inclusion on the MOH List of Subsidised Drugs for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The decision was based on the unfavourable cost-effectiveness of cabotegravir with rilpivirine at the price proposed by the company compared with subsidised oral antiretroviral therapies. Technology Guidance Driving Better
Cabotegravir (Vocabria) and rilpivirine (Rekambys) intramuscular injections in HIV infection Prescrire IN ENGLISH - Spotlight ''Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) intramuscular injections in HIV infection'', 1 April 2022 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 network Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Cabotegravir (Vocabria°) and rilpivirine (Rekambys°) intramuscular injections in HIV infection SpotlightEvery month, the subjects in Prescrire’s Spotlight
Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Rilpivirin (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 July 2021). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A21-48 Rilpivirine (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A21-48 Version 1.0 Rilpivirine (HIV infection) 29 July 2021 Institute for Quality and Efficiency in Health Care
Cabotegravir and rilpivirine (Cabenuva) - To treat HIV Drug Approval Package: VOCABRIA * Skip to main page content * Skip to search * Skip to topics menu * Skip to common linksHHS U.S. Department of Health and Human Services U.S. Food and Drug Administration * Follow FDA * En EspañolSearch FDASubmit search * Popular Content * Home * Food * Drugs * Medical Devices * Radiation-Emitting Products
Cabotegravir and rilpivirine (Vocabria/Cabenuva) - HIV?1 Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More servicesYou are here: 1. HomeSummary Basis
Rilpivirine cabotegravir (cabenuva, vocabria) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical
Bictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV Skip to navigationSkip to contentA-Z MedicinesFAQSubscribeSearchSearchSearch medicinePBS MEDICINE SEARCHHomePBS InformationBrowse the PBSFor Health ProfessionalsFor IndustryNewsPublications & DownloadsContactsHome/ Industry/ Listing/ Participants/ Public Release Docs/ 2021 10/ Bictegravir Emtricitabine Tenofovir Alafenamide And DolutegrBictegravir+emtricitabine+tenofovir alafenamide and dolutegravir+rilpivirine for HIV, October 2021Page last updated: 24 March 2022Drug utilisation sub-committee (DUSC)October 2021AbstractPurposeTo review the predicted versus actual utilisation of bictegravir+emtricitabine+tenofovir alafenamide (Biktarvy) and dolutegravir+rilpivirine (Juluca) in the first 24 months of R/PBS
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African Africa. Participants with HIV viral load below 50 copies per mL on oral antiretroviral therapy and no history of virological failure were randomly assigned (1:1; web-based, permuted blocks) to receive cabotegravir (600 mg) and rilpivirine (900 mg) by intramuscular injection every 8 weeks, or to continue oral therapy. Viral load was monitored every 24 weeks. The primary outcome was week 48 viral load
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use. Pre-existing rilpivirine resistance-associated mutations (RVP-RAMs) have been found to predict HIV-1 virological failure in those switching to long-acting injectable cabotegravir/rilpivirine. We here , M230L, A98G, V179D, G190A, G190E and M230I) were below a prevalence of 1%. RPV-RAMs were present in 10.7% of ART-naive and 13.7% of ART-suppressed PWH in Botswana. The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle income countries. Baseline rilpivirine drug resistance mutations (DRM) are a risk factor for virological failure in patients treated with long-acting cabotegravir plus rilpivirine (CAB/RPV LA). We investigated rilpivirine cross resistance in treatment-naïve and experienced patients in South Africa . One in ten treatment naïve patients and 74.5% of patients failing treatment presented with rilpivirine DRMs. Our data suggest targeted genotyping may be required for patients initiating CAB/RPV LA, which significantly complicates the currently used public health approach.
Dolutegravir + rilpivirine (Juluca) dual therapy in HIV infection Prescrire IN ENGLISH - Spotlight ''Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection'', 1 November 2019 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90Spotlight * 100 most recent
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort. Real-world data showing the long-term effectiveness of long-acting injectable cabotegravir and rilpivirine are scarce. We assessed the effectiveness of cabotegravir and rilpivirine in all individuals who switched to cabotegravir and rilpivirine in the Netherlands. We used data from the ATHENA cohort, an ongoing observational nationwide HIV cohort in the Netherlands. In the primary analysis, we matched individuals who commenced cabotegravir and rilpivirine and had no history of virological failure (ie, one or more measurements of a plasma HIV RNA ≥1000 copies per mL; hereafter referred
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Long-acting cabotegravir and long-acting rilpivirine constitute a completely intramuscular antiretroviral therapy (ART) regimen for adults with HIV. We aimed to assess the safety, antiviral activity, and pharmacokinetics of oral cabotegravir and rilpivirine followed by a combination of long-acting cabotegravir and long-acting rilpivirine in virologically suppressed adolescents with HIV. The IMPAACT 2017/MOCHA study is a phase 1/2, multicentre, open-label, non-comparative, dose-finding trial being conducted at 18 sites across Botswana, South Africa, Thailand
The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis. Fixed dose combination (FDC) dolutegravir (DTG) plus rilpivirine (RPV) is an approved antiretroviral treatment regimen for people with HIV. The steady-state pharmacokinetics of FDC DTG+RPV in hemodialysis has not been previously studied. We performed a single-center, prospective evaluation
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data. Long-acting Cabotegravir and Rilpivirine (LA CAB + RPV) shows potential advantages in heavily comorbid and even in viremic people with HIV (PWH). We assessed LA CAB + RPV durability in a cohort of PWH with a high comorbidity burden and adherence issues